<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38624" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Doxycycline Hyclate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Reema S.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Reema Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38624.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Doxycycline hyclate is a medication used in the management and treatment of a variety of infections. It is in the tetracyclines class of drugs. This activity outlines the indications, action, and contraindications for doxycycline hyclate as a valuable agent in treating and managing skin, dental, respiratory, and urinary tract infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of doxycycline hyclate.</p></list-item><list-item><p>Describe the adverse effects and contraindications of doxycycline hyclate.</p></list-item><list-item><p>Review cases of doxycycline hyclate toxicity and describe the appropriate monitoring process.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst the interprofessional team to enhance the delivery of care for patients with doxycycline hyclate toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38624&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38624">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38624.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Doxycycline&#x000a0;hyclate&#x000a0;is a&#x000a0;water-soluble&#x000a0;tetracycline antibiotic that kills and prevents the growth of a wide range of gram-positive and&#x000a0;-negative bacteria. It plays a role in managing and treating acne, malaria (for prophylaxis and treatment), skin infections, sexually transmitted infections (i.e., chlamydia, syphilis, gonorrhea, pelvic inflammatory disease) Lyme disease. Doxycycline&#x000a0;hyclate&#x000a0;is also effective for treating outbreaks such as cholera, mycoplasma, tularemia, typhus, and Rickettsia infections.<xref ref-type="bibr" rid="article-38624.r1">[1]</xref>&#x000a0;</p>
        <p>Several studies have also proven that tetracyclines, especially doxycycline, contain immunomodulating properties and can be used to control inflammation in diseases such as rheumatoid arthritis.<xref ref-type="bibr" rid="article-38624.r2">[2]</xref>&#x000a0;Tetracyclines, such as doxycycline, have shown effectiveness in treating acne vulgaris, rosacea, bullous dermatoses, granulomatous disease, and livedo vasculitis.<xref ref-type="bibr" rid="article-38624.r3">[3]</xref></p>
        <p>Doxycycline&#x000a0;hyclate&#x000a0;has a specific indication for adult periodontal disease for its&#x000a0;anti-collagenase&#x000a0;and&#x000a0;anti-matrix&#x000a0;metalloproteinase activity in the gingival crevicular fluid. There is no evidence of changes or antibiotic susceptibility to normal periodontal flora or opportunistic pathogens.<xref ref-type="bibr" rid="article-38624.r4">[4]</xref></p>
      </sec>
      <sec id="article-38624.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Doxycycline&#x000a0;hyclate&#x000a0;works systemically in various tissues. Compared to other tetracyclines, its high lipophilicity allows&#x000a0;doxycycline to cross multiple membranes to reach target molecules. Tetracyclines act as cationic coordination complexes to cross the&#x000a0;OmpF&#x000a0;and&#x000a0;OmpC&#x000a0;porin channels in gram-negative bacteria.&#x000a0;Similarly,&#x000a0;in gram-positive bacteria, the electroneutral, lipophilic form traverses the cytoplasmic membrane. Uptake across the cytoplasmic membrane is energy-dependent and driven by the proton motive force.<xref ref-type="bibr" rid="article-38624.r5">[5]</xref>&#x000a0;</p>
        <p>The bacteriostatic action of tetracyclines, like doxycycline&#x000a0;hyclate, is intended to stop the growth of bacteria by allosterically binding to the 30S prokaryotic ribosomal unit during protein synthesis.<xref ref-type="bibr" rid="article-38624.r5">[5]</xref> Doxycycline&#x000a0;hyclate&#x000a0;prevents the association of the charged aminoacyl-tRNA (aa-tRNA) with the ribosomal A site to stall the elongation phase, yielding an unproductive cycle of protein synthesis. Doxycycline affects the binding rate of the ternary complex (comprised of elongation factor Tu (EF-Tu), GTP, and aa-tRNA) to the ribosome.<xref ref-type="bibr" rid="article-38624.r6">[6]</xref>&#x000a0;The ternary complex attempts to bind the aa-tRNA to the A site but fails to do so.<xref ref-type="bibr" rid="article-38624.r7">[7]</xref> This process halts the translation of the growing polypeptide chain,&#x000a0;impeding&#x000a0;the production of essential proteins and eventually killing the bacteria.&#x000a0;&#x000a0;</p>
        <p>Tetracyclines, such as doxycycline&#x000a0;hyclate, present immunomodulating properties that inhibit leukocyte movement during inflammation by preventing calcium-dependent microtubular assembly and lymphocytic proliferation.<xref ref-type="bibr" rid="article-38624.r4">[4]</xref> Doxycycline initiates anti-inflammatory actions in diseases such as osteoarthritis by inhibition of nitric acid synthase.<xref ref-type="bibr" rid="article-38624.r8">[8]</xref>&#x000a0;&#x000a0;</p>
        <p>Bacterial ribosomal protection proteins Tet(O) and Tet(M) employ a variety of resistance mechanisms that include efflux, enzymatic degradation, and rRNA mutations. Tet(O) prevents tetracyclines from attaching to the primary binding site. Tet(O) and Tet(M) displace tetracyclines from the ribosome and increases the&#x000a0;disassociation&#x000a0;constant,&#x000a0;Kd,&#x000a0;and allow the aa-tRNA to bind to the A site so protein synthesis can resume.<xref ref-type="bibr" rid="article-38624.r7">[7]</xref></p>
      </sec>
      <sec id="article-38624.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Administration of Doxycycline Hyclate:&#x000a0;</p>
        <p>
<bold>Bacterial Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For mild to moderate infections, Doxycycline&#x000a0;hyclate&#x000a0;should be taken in doses of 100 mg every 12 hours on the first day and then 100 mg/day onwards. For pelvic infections, the dose is 100 mg twice a day for one week.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The maximum dosage is 300 mg/day, except in the case of acute gonorrheal infection, which is often treated with&#x000a0;600 mg/day for five days.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The drug is best on an empty stomach at least 1 hour before or 2 hours after eating. Take medication with at least 8 ounces of water.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For optimal gastrointestinal absorption, the medication&#x000a0;should be taken 2&#x000a0;to 3 hours before or after consuming any supplements or drugs with magnesium, zinc, calcium, aluminum, iron, or sodium bicarbonate.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Anti-inflammation&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Doxycycline&#x000a0;hyclate&#x000a0;can be taken at sub-acute doses of 40 mg daily for anti-inflammatory effects. The anti-microbial mechanism will not be in action at this sub-antimicrobial dose, sparing healthy bacteria and maintaining the body's microbiome.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Malaria Prevention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Must be taken at 100 mg dose once daily for malaria prophylaxis. Highly recommended to be taken with an adequate amount of fluids and food. The first dose should be taken 1&#x000a0;to 2 days before traveling, and the regimen should continue while traveling in high-risk areas and four more weeks after returning.&#x000a0;Doxycycline&#x000a0;hyclate&#x000a0;should be used in conjunction with&#x000a0;chloroquine.<xref ref-type="bibr" rid="article-38624.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>The course of prescribed doxycycline&#x000a0;hyclate&#x000a0;should be finished in its entirety, even if symptoms disappear sooner.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-38624.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Reactions&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild diarrhea&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Photosensitivity&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nausea&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Vomiting&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Skin rash/itching&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Headaches&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tooth discoloration&#x000a0;</p>
          </list-item>
        </list>
        <p>Doxycycline&#x000a0;hyclate&#x000a0;is a highly tolerated drug compared to its tetracycline counterparts and has limited evidence for causing serious adverse effects. The following are some of the rarely observed adverse events:&#x000a0;</p>
        <p>
<bold>Severe Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bloody diarrhea&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Migraines&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemolytic anemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Throat irritation or trouble swallowing&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chest pain&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Exacerbation of systemic lupus erythematosus&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Shortness of breath&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Irregular or fast heart rate&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dysuria&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Intracranial hypertension&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Esophagitis/esophageal ulcerations if taken without water&#x000a0;</p>
          </list-item>
        </list>
        <p>Researchers described a Type I anaphylactic reaction with hypotension, bronchospasms, and urticaria in a patient who received intravenous doxycycline with a beta-blocker during general anesthesia.<xref ref-type="bibr" rid="article-38624.r10">[10]</xref> They have also observed a unique case of fever, lymphadenopathy, nephritis, hepatitis, and severe pneumonitis with respiratory failure resulting from oral administration of doxycycline.<xref ref-type="bibr" rid="article-38624.r11">[11]</xref></p>
        <p>In rare cases, Doxycycline&#x000a0;hyclate&#x000a0;has also reportedly caused Steven-Johnson Syndrome, potentially life-threatening mucocutaneous eruptions with a diffuse distribution of purpuric macules or targetoid lesions. Treatment usually entails hospitalization and supportive care for symptoms, with the administration of&#x000a0;hydroxyzine hydrochloride, mupirocin ointment,&#x000a0;and prednisone.<xref ref-type="bibr" rid="article-38624.r12">[12]</xref></p>
        <p>Administration of doxycycline with warfarin has&#x000a0;resulted in an enhanced anticoagulant effect due to the competitive interaction for albumin binding and potential inhibition of the cytochrome P-450 pathway.<xref ref-type="bibr" rid="article-38624.r13">[13]</xref></p>
      </sec>
      <sec id="article-38624.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy or breastfeeding&#x000a0;due to teratogenicity and permanent teeth discoloration after in utero exposure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Children under the age of 12&#x000a0;due to teeth discoloration&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Allergy to tetracycline antibiotics&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Use with penicillin or isotretinoin&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Relative Contraindications&#x000a0;&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver disease&#x000a0;due to rare fatal hepatotoxicity&#x000a0;</p>
          </list-item>
          <list-item>
            <p>History of yeast infections&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recent colitis caused by antibiotic use&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Kidney disease diarrhea from&#x000a0;<italic toggle="yes">C.&#x000a0;Dificile&#x000a0;</italic></p>
          </list-item>
          <list-item>
            <p>History of lupus (autoimmune)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Porphyria&#x000a0;(a blood disease)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38624.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Doxycycline hyclate has proven to have an effective therapeutic spectrum. Oral administration is&#x000a0;most common, but delivery can also via an IV if necessary. An oral dose of 100&#x000a0;to 200 mg is absorbed rapidly. Data shows doxycycline was detectable in the blood as soon as 15 minutes after administration. It has a reported peak plasma concentration of 1.7&#x000a0;to 5.9 mg/mL after 2&#x000a0;to 3 hours and an elimination half-life of 15 to 30 hours.<xref ref-type="bibr" rid="article-38624.r14">[14]</xref> Doxycycline&#x000a0;hyclate&#x000a0;metabolism mainly occurs in the duodenum.<xref ref-type="bibr" rid="article-38624.r15">[15]</xref> Elimination primarily occurs through the gastrointestinal tract, but 30&#x000a0;to 40% occurs through renal excretion.<xref ref-type="bibr" rid="article-38624.r4">[4]</xref>&#x000a0;</p>
        <p>There are no standard routine tests to monitor the use of doxycycline. The most significant side effect is hepatic injury, which can be avoided by administering doxycycline&#x000a0;hyclate&#x000a0;at the recommended dosage and keeping contraindications and adverse effects in mind.&#x000a0;&#x000a0;</p>
        <p>Tetracyclines are contraindicated in pregnancy, lactation, and children under 12&#x000a0;due&#x000a0;to proven human teratogenic effects, yet there is no evidence against doxycycline specifically.<xref ref-type="bibr" rid="article-38624.r1">[1]</xref></p>
      </sec>
      <sec id="article-38624.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In rare instances, doxycycline has correlated with hepatic injury about 1 to 2 weeks after starting therapy. Hepatic injury can range from hepatocellular to cholestatic or mixed. There is often a quick onset with reported symptoms of DRESS syndrome, such as rash, fever, and eosinophilia.<xref ref-type="bibr" rid="article-38624.r16">[16]</xref></p>
        <p>Acute doxycycline hepatitis was noted in a patient receiving treatment of pulmonary&#x000a0;actinomycosis&#x000a0;after 1.5 months of 200 mg/daily dose of doxycycline. Liver function tests showed markedly elevated ALT, AST, ALP, and GGT. Liver biopsy demonstrated&#x000a0;centrilobular&#x000a0;necrosis, indicative of toxic hepatitis.<xref ref-type="bibr" rid="article-38624.r17">[17]</xref> A liver reaction with non-specific hepatitis appeared within 24 hours of oral doxycycline therapy in a patient with a suspected pneumonia infection. The diagnosis was confirmed with liver biopsy showing cholestasis and inflammation as well as increased liver enzymes (ALT, AST, ALP).<xref ref-type="bibr" rid="article-38624.r18">[18]</xref> Rapid recovery is expected within 4 to 6 weeks after discontinuation of doxycycline&#x000a0;hyclate&#x000a0;and treatment with corticosteroids.<xref ref-type="bibr" rid="article-38624.r12">[12]</xref></p>
      </sec>
      <sec id="article-38624.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians need to be more diligent when prescribing doxycycline to avoid a dangerous drug-resistant infection. Doxycycline&#x000a0;hyclate&#x000a0;therapy requires an interprofessional team approach, with clinicians, nurses, and pharmacists all collaborating to achieve optimal patient results. Since adverse effects are rare and varied in symptoms, it is crucial for those involved in the care of patients undergoing doxycycline&#x000a0;hyclate&#x000a0;therapy to understand the mechanism of action, dosing protocols, and signs of toxicity. If toxicity occurs, normal liver function should be confirmed with liver enzyme tests and biopsy, if required. The clinician and pharmacist are responsible for medication reconciliation to prevent drug-drug interactions. After the patient stabilizes, the healthcare team should determine the reason for toxicity and potentially report any new findings. Interprofessional care will result in better patient outcomes and fewer adverse events with doxycycline. [Level 5]</p>
      </sec>
      <sec id="article-38624.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38624&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38624">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38624/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38624">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38624.s11">
        <title>References</title>
        <ref id="article-38624.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>McGready</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paris</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2016</year>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-82</page-range>
            <pub-id pub-id-type="pmid">26680308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sapadin</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Fleischmajer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tetracyclines: nonantibiotic properties and their clinical implications.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-65</page-range>
            <pub-id pub-id-type="pmid">16443056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Del Rosso</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>Anti-inflammatory activity of tetracyclines.</article-title>
            <source>Dermatol Clin</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-5, v</page-range>
            <pub-id pub-id-type="pmid">17430750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valent&#x000ed;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of doxycycline in the treatment of rosacea.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2009</year>
            <month>Aug</month>
            <day>12</day>
            <volume>2</volume>
            <fpage>129</fpage>
            <page-range>129-40</page-range>
            <pub-id pub-id-type="pmid">21436975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chopra</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.</article-title>
            <source>Microbiol Mol Biol Rev</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-60 ; second page, table of contents</page-range>
            <pub-id pub-id-type="pmid">11381101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodersen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Clemons</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Morgan-Warren</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wimberly</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit.</article-title>
            <source>Cell</source>
            <year>2000</year>
            <month>Dec</month>
            <day>22</day>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>1143</fpage>
            <page-range>1143-54</page-range>
            <pub-id pub-id-type="pmid">11163189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connell</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tracz</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nierhaus</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Ribosomal protection proteins and their mechanism of tetracycline resistance.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>12</issue>
            <fpage>3675</fpage>
            <page-range>3675-81</page-range>
            <pub-id pub-id-type="pmid">14638464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chukwudi</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>4433</fpage>
            <page-range>4433-41</page-range>
            <pub-id pub-id-type="pmid">27246781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Magill</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Parise</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Arguin</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>84</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-31</page-range>
            <pub-id pub-id-type="pmid">21460003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Guarascio</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Tetracycline Allergy.</article-title>
            <source>Pharmacy (Basel)</source>
            <year>2019</year>
            <month>Aug</month>
            <day>03</day>
            <volume>7</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31382572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robles</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Waghmare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McDonough</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolgamot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fleckman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Severe drug hypersensitivity reaction in a young woman treated with doxycycline.</article-title>
            <source>Dermatology</source>
            <year>2008</year>
            <volume>217</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-6</page-range>
            <pub-id pub-id-type="pmid">18332631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cac</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Messingham</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sniezek</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Walling</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson syndrome induced by doxycycline.</article-title>
            <source>Cutis</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-22</page-range>
            <pub-id pub-id-type="pmid">17388211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasan</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Interaction of doxycycline and warfarin: an enhanced anticoagulant effect.</article-title>
            <source>Cornea</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>742</fpage>
            <page-range>742-3</page-range>
            <pub-id pub-id-type="pmid">17592328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucchetti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fracasso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Balducci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Passoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Forloni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salmona</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gobbi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>368</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-40</page-range>
            <pub-id pub-id-type="pmid">30396916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sloan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scheinfeld</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The use and safety of doxycycline hyclate and other second-generation tetracyclines.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>571</fpage>
            <page-range>571-7</page-range>
            <pub-id pub-id-type="pmid">18759709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mailhol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tremeau-Martinage</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Godel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lamant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giordano-Labadie</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Severe drug hypersensitivity reaction (DRESS syndrome) to doxycycline].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-3</page-range>
            <pub-id pub-id-type="pmid">20110067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chavant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lafay-Chebassier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beauchant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perault-Pochat</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>[Doxycycline induced hepatitis].</article-title>
            <source>Gastroenterol Clin Biol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>825</fpage>
            <page-range>825-7</page-range>
            <pub-id pub-id-type="pmid">18823729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38624.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lindberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Liver reactions to oral low-dose tetracyclines.</article-title>
            <source>Scand J Gastroenterol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-5</page-range>
            <pub-id pub-id-type="pmid">9140164</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
